Karyopharm Therapeutics (KPTI) Q2 2024 earnings summary

Executive summary

• Advanced late-stage pipeline with pivotal phase 3 trials for selinexor in myelofibrosis, endometrial cancer, and multiple myeloma, supported by strong clinical and preclinical data and ongoing regulatory submissions.

• Achieved Q2 2024 net income of $23.8 million, reversing a net loss of $32.6 million in Q2 2023, driven by a $44.7 million non-cash gain on extinguishment of debt and other non-cash gains.

• Total Q2 2024 revenue reached $42.8 million, up from $37.6 million in Q2 2023, with license and milestone revenue growth offsetting a slight decline in product revenue.

• Global commercial presence with XPOVIO approvals in over 40 countries, expanded reimbursement, and strong community setting demand growth.

• Significant refinancing in May 2024 extended most debt maturities to 2028–2029, improving financial flexibility and reducing future royalty obligations.

Financial highlights

• Q2 2024 total revenue was $42.8 million (Q2 2023: $37.6 million); net product revenue was $28.0 million (Q2 2023: $28.5 million); license/other revenue was $14.8 million (Q2 2023: $9.1 million).

• Net income for Q2 2024 was $23.8 million, compared to a net loss of $32.6 million in Q2 2023, aided by a $44.7 million non-cash gain on debt extinguishment.

• R&D expenses rose to $38.4 million (Q2 2024) from $31.5 million (Q2 2023); SG&A expenses decreased to $31.1 million from $34.5 million.

• Cash, cash equivalents, and investments totaled $152.5 million as of June 30, 2024.

• Interest expense increased to $8.9 million in Q2 2024 due to new term loan and convertible notes.

Outlook and guidance

• Raised lower end of 2024 total revenue guidance to $145 million–$160 million and XPOVIO net US product revenue to $105 million–$120 million.

• Lowered and tightened 2024 R&D and SG&A expense guidance to $250 million–$265 million.

• Cash runway expected into early 2026, excluding repayment of convertible notes due 2025 and $25 million minimum liquidity covenant.

• Top-line data from pivotal trials in multiple myeloma (1H 2025), myelofibrosis (2H 2025), and endometrial cancer (early 2026) anticipated.

• Product revenue expected to slightly increase in the second half of 2024; license and other revenue anticipated to decrease slightly.